Pinnacle Wealth Planning Services Inc. Has $249,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Pinnacle Wealth Planning Services Inc. trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 34.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,098 shares of the medical instruments supplier’s stock after selling 576 shares during the quarter. Pinnacle Wealth Planning Services Inc.’s holdings in Becton, Dickinson and Company were worth $249,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter worth $181,279,000. Proficio Capital Partners LLC acquired a new position in Becton, Dickinson and Company during the 4th quarter valued at $21,607,000. M&T Bank Corp raised its stake in Becton, Dickinson and Company by 3.6% during the 4th quarter. M&T Bank Corp now owns 55,001 shares of the medical instruments supplier’s stock valued at $12,478,000 after purchasing an additional 1,899 shares during the last quarter. Assetmark Inc. raised its stake in Becton, Dickinson and Company by 51.0% during the 4th quarter. Assetmark Inc. now owns 51,180 shares of the medical instruments supplier’s stock valued at $11,611,000 after purchasing an additional 17,292 shares during the last quarter. Finally, Smithfield Trust Co raised its stake in Becton, Dickinson and Company by 2.8% during the 4th quarter. Smithfield Trust Co now owns 4,056 shares of the medical instruments supplier’s stock valued at $920,000 after purchasing an additional 110 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. This represents a 8.01 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 700 shares of the stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total transaction of $159,593.00. Following the sale, the director now directly owns 36,033 shares in the company, valued at approximately $8,215,163.67. This represents a 1.91 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,061 shares of company stock valued at $1,379,521. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Trading Up 1.8 %

Shares of BDX stock opened at $229.51 on Friday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The stock has a market cap of $65.90 billion, a price-to-earnings ratio of 38.12, a P/E/G ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The firm has a fifty day moving average of $232.98 and a 200-day moving average of $232.73.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has approved a share repurchase program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 1.81%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 69.10%.

Wall Street Analyst Weigh In

Several research firms recently commented on BDX. Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, Barclays upped their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Buy” and a consensus target price of $278.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.